Phase
Condition
Seizure Disorders (Pediatric)
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Subjects (male or female) must be > 18 years of age, with a diagnosis of epilepsy withpartial seizures, as defined in the International League Against Epilepsy (ILAE)classification of seizures.
- Partial seizures may be simple or complex, with or without secondary tonic-clonicgeneralization.
- Subjects must be have been diagnosed with epilepsy for at least 2 years, and must havebeen unresponsive to treatment with at least two but no more than five priorantiepileptic drugs (AEDs), and at the time of study enrollment are on stable dosagesof 1 or 2 standard AEDs.
Exclusion
Exclusion Criteria:
- Females who are pregnant, breastfeeding, or intend to become pregnant during thecourse of the trial will be excluded
- Subjects with other neurologic illness that could impair endpoint assessment, orsubjects with Lennox-Gastaut syndrome, absence seizures, status epileptics within the 12 months prior to trial entry, or with seizures due to an underlying medical illnessor metabolic syndrome, will be excluded.
Study Design
Connect with a study center
Pfizer Investigational Site
Duffel, B-2570
BelgiumSite Not Available
Pfizer Investigational Site
Yvoir, B-5530
BelgiumSite Not Available
Pfizer Investigational Site
Kyustendil 2500,
BulgariaSite Not Available
Pfizer Investigational Site
Pernik, 2300
BulgariaSite Not Available
Pfizer Investigational Site
Plovdiv, 4000
BulgariaSite Not Available
Pfizer Investigational Site
Ruse 7002,
BulgariaSite Not Available
Pfizer Investigational Site
Sofia, 1407
BulgariaSite Not Available
Pfizer Investigational Site
Barranquilla, Atlantico 0
ColombiaSite Not Available
Pfizer Investigational Site
Bogota, Cundinamarca 0
ColombiaSite Not Available
Pfizer Investigational Site
Montes De Oca, San Jose
Costa RicaSite Not Available
Pfizer Investigational Site
San Jose,
Costa RicaSite Not Available
Pfizer Investigational Site
Brno, 602 00
CzechiaSite Not Available
Pfizer Investigational Site
Brno 2, 602 00
CzechiaSite Not Available
Pfizer Investigational Site
Hradec Kralove 3, 500 03
CzechiaSite Not Available
Pfizer Investigational Site
Olomouc, 775 20
CzechiaSite Not Available
Pfizer Investigational Site
Ostrava-Trebovice, 772 00
CzechiaSite Not Available
Pfizer Investigational Site
Praha 4, 140 59
CzechiaSite Not Available
Pfizer Investigational Site
Pribram 8, 26195
CzechiaSite Not Available
Pfizer Investigational Site
Rychnov nad Kneznou, 516 01
CzechiaSite Not Available
Pfizer Investigational Site
Strasbourg Cedex, 67091
FranceSite Not Available
Pfizer Investigational Site
Toulouse, 31043
FranceSite Not Available
Pfizer Investigational Site
Bonn, 53105
GermanySite Not Available
Pfizer Investigational Site
Hamburg, 22083
GermanySite Not Available
Pfizer Investigational Site
Athens, 11521
GreeceSite Not Available
Pfizer Investigational Site
Thessaloniki, 57010
GreeceSite Not Available
Pfizer Investigational Site
Pune, Maharashtra 411 004
IndiaSite Not Available
Pfizer Investigational Site
Chandigarh, Punjab 160 012
IndiaSite Not Available
Pfizer Investigational Site
Ludhiana, Punjab 141 008
IndiaSite Not Available
Pfizer Investigational Site
Firenze, 50125
ItalySite Not Available
Pfizer Investigational Site
Foggia, 71100
ItalySite Not Available
Pfizer Investigational Site
Pisa, 56126
ItalySite Not Available
Pfizer Investigational Site
Siena, 53100
ItalySite Not Available
Pfizer Investigational Site
Busan, 602-715
Korea, Republic ofSite Not Available
Pfizer Investigational Site
Daejeon, 301-721
Korea, Republic ofSite Not Available
Pfizer Investigational Site
Seoul, 135-710
Korea, Republic ofSite Not Available
Pfizer Investigational Site
Kaunas, 50009
LithuaniaSite Not Available
Pfizer Investigational Site
Vilnius, 08661
LithuaniaSite Not Available
Pfizer Investigational Site
Distrito Federal, 14269
MexicoSite Not Available
Pfizer Investigational Site
San Luis Potosi, 78223
MexicoSite Not Available
Pfizer Investigational Site
Panama,
PanamaSite Not Available
Pfizer Investigational Site
Lima, Lima 1
PeruSite Not Available
Pfizer Investigational Site
Tondo, Manila 1000
PhilippinesSite Not Available
Pfizer Investigational Site
Cebu City, 6000
PhilippinesSite Not Available
Pfizer Investigational Site
Davao City, 8000
PhilippinesSite Not Available
Pfizer Investigational Site
Makati City, 1200
PhilippinesSite Not Available
Pfizer Investigational Site
Manila, 1000
PhilippinesSite Not Available
Pfizer Investigational Site
Quezon City, 1100
PhilippinesSite Not Available
Pfizer Investigational Site
Moscow, 129128
Russian FederationSite Not Available
Pfizer Investigational Site
St. Petersburg, 194044
Russian FederationSite Not Available
Pfizer Investigational Site
Donostia, Guipuzcoa 20014
SpainSite Not Available
Pfizer Investigational Site
Alicante, 03010
SpainSite Not Available
Pfizer Investigational Site
Barcelona, 08035
SpainSite Not Available
Pfizer Investigational Site
Cordoba, 14008
SpainSite Not Available
Pfizer Investigational Site
Girona, 17007
SpainSite Not Available
Pfizer Investigational Site
Sevilla, 41071
SpainSite Not Available
Pfizer Investigational Site
Kaohsiung, 807
TaiwanSite Not Available
Pfizer Investigational Site
Taichung, 407
TaiwanSite Not Available
Pfizer Investigational Site
Tainan, 704
TaiwanSite Not Available
Pfizer Investigational Site
Capa, Istanbul 34390
TurkeySite Not Available
Pfizer Investigational Site
Ankara, 06100
TurkeySite Not Available
Pfizer Investigational Site
Cerrahpasa / Istanbul, 34098
TurkeySite Not Available
Pfizer Investigational Site
Caracas, Miranda 1080-A
VenezuelaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.